Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to $20.6 million.

  • Ovid Therapeutics' Cash & Equivalents rose 3725.11% to $20.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.6 million, marking a year-over-year increase of 3725.11%. This contributed to the annual value of $26.3 million for FY2024, which is 274.02% down from last year.
  • Latest data reveals that Ovid Therapeutics reported Cash & Equivalents of $20.6 million as of Q3 2025, which was up 3725.11% from $28.4 million recorded in Q2 2025.
  • Ovid Therapeutics' Cash & Equivalents' 5-year high stood at $233.1 million during Q1 2021, with a 5-year trough of $15.0 million in Q3 2024.
  • Its 5-year average for Cash & Equivalents is $82.7 million, with a median of $57.4 million in 2023.
  • As far as peak fluctuations go, Ovid Therapeutics' Cash & Equivalents surged by 75251.57% in 2021, and later tumbled by 7610.84% in 2022.
  • Quarter analysis of 5 years shows Ovid Therapeutics' Cash & Equivalents stood at $187.8 million in 2021, then crashed by 76.11% to $44.9 million in 2022, then tumbled by 39.73% to $27.0 million in 2023, then decreased by 2.74% to $26.3 million in 2024, then decreased by 21.63% to $20.6 million in 2025.
  • Its Cash & Equivalents was $20.6 million in Q3 2025, compared to $28.4 million in Q2 2025 and $21.1 million in Q1 2025.